Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | CFTR | P13569 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 5/20 | 0.36 |
| ▸ | NPC1 | O15118 | 4/20 | 0.36 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.35 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14239972 | 0.86 | LMNA (0.38) | LMNACYP2C19KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL20756325 | 0.84 | SMN1; SMN2 (0.50) | LMNACYP2C19KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL2053715 | 0.82 | RAB9A (0.44) | LMNACYP2C19KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL14239083 | 0.82 | ALDH1A1 (0.49) | LMNACYP2C19KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL17515464 | 0.82 | ALDH1A1 (0.37) | LMNACYP2C19KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL9994567 | 0.82 | NPC1 (0.41) | LMNAALDH1A1TDP1SMN1; SMN2RAB9A | |
| SCHEMBL6923280 | 0.82 | NPC1 (0.41) | LMNAALDH1A1TDP1SMN1; SMN2RAB9A | |
| SCHEMBL15818555 | 0.81 | RAB9A (0.42) | LMNACYP2C19KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL14238853 | 0.81 | RAB9A (0.42) | LMNACYP2C19KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL9994704 | 0.81 | L3MBTL1 (0.41) | LMNAL3MBTL1SMN1; SMN2RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10640510-B2 | Metabotrophic glutamate receptor 5 modulators and methods use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2020-05-05 | — | — | US | disclosed |
| US-10640510-B2 | Metabotrophic glutamate receptor 5 modulators and methods use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2020-05-05 | — | — | US | disclosed |
| US-20200079778-A9 | METABOTROPHIC GLUTAMATE RECEPTOR 5 MODULATORS AND METHODS USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2020-03-12 | — | — | US | disclosed |
| US-20190135815-A1 | METABOTROPHIC GLUTAMATE RECEPTOR 5 MODULATORS AND METHODS USE THEREOF | SUNOVION PHARMACEUTICALS INC (US) | 2019-05-09 | — | — | US | disclosed |
| US-20190135815-A1 | METABOTROPHIC GLUTAMATE RECEPTOR 5 MODULATORS AND METHODS USE THEREOF | SUNOVION PHARMACEUTICALS INC (US) | 2019-05-09 | — | — | US | disclosed |
| US-10196399-B2 | Metabotrophic glutamate receptor 5 modulators and methods use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2019-02-05 | — | — | US | disclosed |
| US-10196399-B2 | Metabotrophic glutamate receptor 5 modulators and methods use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2019-02-05 | — | — | US | disclosed |
| US-20180037585-A1 | METABOTROPHIC GLUTAMATE RECEPTOR 5 MODULATORS AND METHODS USE THEREOF | SUNOVION PHARAMCEUTICALS INC. | 2018-02-08 | — | — | US | disclosed |
| US-20180037585-A1 | METABOTROPHIC GLUTAMATE RECEPTOR 5 MODULATORS AND METHODS USE THEREOF | SUNOVION PHARAMCEUTICALS INC. | 2018-02-08 | — | — | US | disclosed |
| US-20180037585-A1 | METABOTROPHIC GLUTAMATE RECEPTOR 5 MODULATORS AND METHODS USE THEREOF | SUNOVION PHARAMCEUTICALS INC. | 2018-02-08 | — | — | US | disclosed |
| US-9708331-B2 | Metabotrophic glutamate receptor 5 modulators and methods of use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-9708331-B2 | Metabotrophic glutamate receptor 5 modulators and methods of use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-20160251359-A1 | METABOTROPHIC GLUTAMATE RECEPTOR 5 MODULATORS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2016-09-01 | — | — | US | disclosed |
| US-9260452-B2 | Metabotrophic glutamate receptor 5 modulators and methods of use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2016-02-16 | — | — | US | disclosed |
| US-9260452-B2 | Metabotrophic glutamate receptor 5 modulators and methods of use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2016-02-16 | — | — | US | disclosed |
| US-9260452-B2 | Metabotrophic glutamate receptor 5 modulators and methods of use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2016-02-16 | — | — | US | disclosed |
| US-20140179682-A1 | METABOTROPHIC GLUTAMATE RECEPTOR 5 MODULATORS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2014-06-26 | — | — | US | disclosed |
| US-20140179682-A1 | METABOTROPHIC GLUTAMATE RECEPTOR 5 MODULATORS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2014-06-26 | — | — | US | disclosed |
| US-20140179682-A1 | METABOTROPHIC GLUTAMATE RECEPTOR 5 MODULATORS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2014-06-26 | — | — | US | disclosed |
| WO-2012170845-A2 | METABOTROPIC GLUTAMATE RECEPTOR 5 MODULATORS AND METHODS OF USE THEREOF | HEFFERNAN MICHELE L R (US) | 2012-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10196399-B2 | Metabotrophic glutamate receptor 5 modulators and methods use thereof | GRM5, GRIK5, GRM2 | LMNA 4858/4885CYP2C19 3895/4885KDM4E 2910/4885 |
| US-20180037585-A1 | METABOTROPHIC GLUTAMATE RECEPTOR 5 MODULATORS AND METHODS USE THEREOF | GRM5, GRIK5, GRM2 | LMNA 4858/4885CYP2C19 3895/4885KDM4E 2910/4885 |
| US-20160251359-A1 | METABOTROPHIC GLUTAMATE RECEPTOR 5 MODULATORS AND METHODS OF USE THEREOF | GRM5, GRIK5, GRM2 | LMNA 4870/4885CYP2C19 3386/4885KDM4E 3093/4885 |
| US-20190135815-A1 | METABOTROPHIC GLUTAMATE RECEPTOR 5 MODULATORS AND METHODS USE THEREOF | GRM5, GRIK5, GRM2 | LMNA 4858/4885CYP2C19 3895/4885KDM4E 2910/4885 |
| US-20200079778-A9 | METABOTROPHIC GLUTAMATE RECEPTOR 5 MODULATORS AND METHODS USE THEREOF | GRM5, GRIK5, GRM2 | LMNA 4858/4885CYP2C19 3895/4885KDM4E 2910/4885 |
| US-10640510-B2 | Metabotrophic glutamate receptor 5 modulators and methods use thereof | GRM5, GRIK5, GRM2 | LMNA 4858/4885CYP2C19 3895/4885KDM4E 2910/4885 |
| US-20140179682-A1 | METABOTROPHIC GLUTAMATE RECEPTOR 5 MODULATORS AND METHODS OF USE THEREOF | GRM5, GRIK5, GRM2 | LMNA 4870/4885CYP2C19 3386/4885KDM4E 3093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.